

BIO-AMOKSIKLAV 375

PATIENT INFORMATION LEAFLET

SCHEDULING STATUS:

[S4]

PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM

BIO-AMOKSIKLAV 375. Each tablet contains amoxicillin trihydrate equivalent to 250 mg amoxicillin and potassium clavulanate equivalent to 125 mg clavulanic acid.

Read all of this leaflet carefully before you start taking BIO-AMOKSIKLAV 375

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.
- BIO-AMOKSIKLAV has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

1. WHAT BIO-AMOKSIKLAV CONTAINS

BIO-AMOKSIKLAV 375: Each film-coated tablet contains amoxicillin trihydrate equivalent to amoxicillin 250 mg and clavulanate potassium equivalent to clavulanic acid 125 mg as the active ingredients. The other ingredients are: Colloidal anhydrous silica, croscarmellose sodium, crospovidone, ethylcellulose, hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, polysorbate 80, talc, titanium dioxide and triethyl citrate.

Sugar free.

2. WHAT BIO-AMOKSIKLAV IS USED FOR

BIO-AMOKSIKLAV can be used for infections that are resistant to amoxicillin, when the beta-lactamases (enzymes produced by the bacteria) are clavulanic acid sensitive.

BIO-AMOKSIKLAV can thus be used for the treatment of:

- upper respiratory tract infections (including sinusitis)
- recurrent middle-ear infections,
- tonsillitis
- lower respiratory tract infections, such as bronchitis and bronchopneumonia
- genito-urinary tract infections, such as cystitis, urethritis, pyelonephritis
- skin and soft tissue infections.

3. BEFORE YOU TAKE BIO-AMOKSIKLAV

Do not take BIO-AMOKSIKLAV:

- if you are hypersensitive (allergic) to penicillins, cephalosporins, cephemycins, or beta-lactamase inhibitors or any of the other ingredients of BIO-AMOKSIKLAV.
- if you have previously had jaundice or liver problems, after taking antibiotics containing amoxicillin / clavulanic acid.

Take special care with BIO-AMOKSIKLAV:

- if you have impaired liver or kidney function
- if you have infectious mononucleosis
- if you have a history of hypersensitivity reactions to penicillins, cephalosporins or other allergens. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins.
- if you take allopurinol, as it can increase your risk of an allergic skin reaction
- if, at the start of treatment, you develop a fever and a rash, it may be a symptom of Acute Generalised Exanthemous Pustulosis (refer to "SIDE EFFECTS")
- if you are on prolonged treatment with BIO-AMOKSIKLAV, as it may result in an over growth of non-susceptible organisms
- if you suffer of severe diarrhoea, during or after using BIO-AMOKSIKLAV, as it may be a symptom of antibiotic-associated colitis. It can range in severity from mild, to life threatening. If your doctor diagnoses you with this condition, treatment with BIO-AMOKSIKLAV should be stopped, and appropriate treatment initiated. You must avoid anti-peristaltic medicines in this situation
- if you take anti-coagulation (anti-blood clotting) medicine (see "Using other medicines with BIO-AMOKSIKLAV" below)
- if you are on prolonged therapy with BIO-AMOKSIKLAV, your doctor should do periodic assessment of your organ functions
- if you have syphilis, as the Jarisch-Herxheimer reaction may occur
- you must maintain adequate fluid intake, especially if you are on prolonged treatment with BIO-AMOKSIKLAV
- if you are on a low-sodium diet, you should take the sodium content of BIO-AMOKSIKLAV into consideration if you are on a high dosage regimen
- The use of BIO-AMOKSIKLAV may lead to the selection of resistant strains of organisms, and sensitivity testing should, whenever possible, be done to demonstrate appropriateness of therapy
- if you are using an oral contraceptive (the Pill), as BIO-AMOKSIKLAV may reduce the efficacy of your oral contraceptive.

Taking BIO-AMOKSIKLAV with food and drink:

These tablets should be taken with food.

The most common side-effects are nausea, vomiting and diarrhoea. Taking the medicine with food can reduce these gastrointestinal symptoms.

Pregnancy and Breastfeeding:

If you are pregnant or breastfeeding your baby, please consult your doctor, pharmacist or other healthcare professional for advice before taking this medicine.

The safety of BIO-AMOKSIKLAV during pregnancy has not been established.

Amoxicillin, an active ingredient of BIO-AMOKSIKLAV, is excreted in breast milk, it may lead to the infant experiencing side effects of BIO-AMOKSIKLAV. Caution should be exercised when a breastfeeding woman uses BIO-AMOKSIKLAV.

Driving and using machinery:

Side effects such as allergic reactions, dizziness and convulsions may occur, which can influence your ability to drive and use machines. You should make sure how BIO-AMOKSIKLAV affects you, before driving and using machines.

Using other medicines with BIO-AMOKSIKLAV

Always tell your healthcare professional if you are taking any other medicine. (This includes complementary or traditional medicines.)

The following medication may interact with BIO-AMOKSIKLAV and therefore you should notify your doctor or healthcare professional if you are taking medicines that contains any of the following before taking BIO-AMOKSIKLAV:

- probencid (anti-gout medication), the simultaneous use with BIO-AMOKSIKLAV is not recommended
- tetracyclines and other bacteriostatic medicines, as it may interfere with the efficacy of BIO-AMOKSIKLAV
- allopurinol (anti-gout medication), as well as ampicillin, as it may increase your risk of an allergic skin reaction
- oral contraceptives (the Pill), (refer to "Take special care with BIO-AMOKSIKLAV" section) above
- warfarin, coumarin or any other anti-clotting medicines
- methotrexate, as BIO-AMOKSIKLAV can increase the toxicity of methotrexate
- mycophenolate mofetil, your dosage of mycophenolate mofetil may need to be adjusted.

Interaction of BIO-AMOKSIKLAV with laboratory tests:

BIO-AMOKSIKLAV may interfere with the results of the following laboratory tests:

- tests for glucose in the urine
- Coombs test
- Aspergillus EIA tests.

4. HOW TO TAKE BIO-AMOKSIKLAV TABLETS

Do not share medicines prescribed for you with any other person.

BIO-AMOKSIKLAV 375: 1 or 2 tablets must be taken every eight hours.

Always take BIO-AMOKSIKLAV exactly as your doctor has instructed you. You should check with your doctor or pharmacist if you are unsure.

If you suffer from kidney problems, your doctor may adjust or reduce the dosage.

Your doctor will tell you how long your treatment will last, do not stop treatment early. You must complete your course of BIO-AMOKSIKLAV. If you have the impression that the effect of BIO-AMOKSIKLAV is too strong or too weak, tell your doctor or pharmacist.

If you take more BIO-AMOKSIKLAV than you should

In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison control centre.

If you forget to take BIO-AMOKSIKLAV

If you miss a dose do not worry, take it as soon as you remember. Do not take a double dose to make up for forgotten individual doses.

5. POSSIBLE SIDE EFFECTS

BIO-AMOKSIKLAV can have side effects. Not all side effects reported for BIO-AMOKSIKLAV are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking BIO-AMOKSIKLAV, please consult your doctor, pharmacist or other healthcare professional for advice.

If any of the following happens, stop taking BIO-AMOKSIKLAV and tell your doctor immediately or go to the casualty department at your nearest hospital:

Frequent serious side effects are:

- persistent or recurrent superficial infections of the skin, mucous membranes and nails with Candida organisms (known as mucocutaneous candidiasis)
- antibiotic associated colitis (severe diarrhoea).

Less frequent serious side effects are:

- certain blood conditions characterised by pale skin, weakness, breathlessness, easy bruising, prolonged bleeding from cuts, bleeding from nose or gums, blood in urine or stools, reddish purple spots on skin
- convulsions (fits).

Serious side effects with unknown frequency are:

- interstitial nephritis, it is a condition characterised by blood in urine, increased or decreased urine output, fluid retention.

Tell your doctor if you notice any of the following:

Frequent side effects are:

- nausea, vomiting, diarrhoea, gastritis, indigestion, abdominal pain, inflammation of the mouth and tongue and black 'hairy' tongue
- tiredness
- hot flushes.

Less frequent side effects are:

- hyperactivity
- dizziness
- headache
- abnormal taste.

Side effects with unknown frequency are:

- cloudy urine.

If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

6. STORING AND DISPOSING OF BIO-AMOKSIKLAV

Keep your tablets in the bottle or blister they came in. Do not put it in another container. Keep the bottle closed tightly and do not remove the desiccant.

Store the tablets at or below 25 °C.

Protect the tablets from moisture and light.

Store all medicines out of reach of children.

The EXPIRY date is marked on the bottle. Do not use the tablets past the expiry date.

Return all unused medicines to your pharmacist.

Do not dispose of unused medicines in drains or sewerage systems (e.g. toilets).

7. PRESENTATION OF BIO-AMOKSIKLAV

BIO-AMOKSIKLAV 375: Tablets are packed in either amber glass containers containing 15 tablets or aluminium blister strip containing 5 tablets. Three blister strips are packed in an outer carton.

8. IDENTIFICATION OF BIO-AMOKSIKLAV

BIO-AMOKSIKLAV 375: White to almost white, octagonal, biconvex film-coated tablets, debossed with 250/125 on one side and AMC on the other side.

9. REGISTRATION NUMBER

BIO-AMOKSIKLAV 375: 31/20.1.2/0681

10. NAME AND ADDRESS OF REGISTRATION HOLDER

Biotech Laboratories (Pty) Ltd.

Block K West, Central Park,

400 16th Road, Halfway House,

Midrand, 1685.

Tel: +27 (11) 848 3050

11. DATE OF PUBLICATION

Date of Registration:

BIO-AMOKSIKLAV 375: 23 August 1999

Date of latest revision of the text as approved by Council: 11 March 2010

Date of notification regarding amended Reg. 9 and 10: 06 February 2015

